New molecular markers within the chronic myeloproliferative disorders. II: The JAK2 mutation;Nye molekylære markører ved de kroniske myeloproliferative sygdomme: II. Janus tyrosinkinase 2-mutationen

Ugeskrift for Laeger

Volumn 168, Issue 39, 2006, Pages 3299-3303

  Larsen, Thomas Stauffer ^a   Pallisgaard, Niels ^a   Christensen, Jacob Haaber ^a   Gram Hansen, Paul ^a   Kerndrup, Gitte B ^a   Møller, Michael Boe ^a   Hasselbalch, Hans Carl ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; JANUS KINASE 2; PHENYLALANINE; VALINE; BIOLOGICAL MARKER; JAK2 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

AMINO ACID SUBSTITUTION; DISEASE CLASSIFICATION; ENZYME ACTIVITY; HEMATOPOIESIS; HUMAN; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; REVIEW; UNITED STATES; BLOOD; CHRONIC MYELOID LEUKEMIA; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; MUTATION; MYELOFIBROSIS; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; SIGNAL TRANSDUCTION; THROMBOCYTOSIS;

BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, CHRONIC; MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; THROMBOCYTOSIS;

EID: 33749239401     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
2. Goldman JM, Melo JV. Chronic myeloid leukaemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
3. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
4. James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
5. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
6. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
7. Steensma DP, Dewald GW, Lasho TL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005;106:1207-9.
8. Jones AV, Kreil S, Zoi K et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005;106:2162-8.
9. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92.
10. Yamaoka K, Saharinen P, Pesu M et al. The Janus kinases (Jaks). Genome Biol 2004;5:253.
11. Silvennoinen O, Saharinen P, Paukka K et al. Cytokine receptor signal transduction through Jak tyrosine kinases and Stat transcription factors. APMIS 1997;105:497-509.
12. JM Goldman. A unifying mutation in chronic myeloproliferative disorders. N Engl J Med 2005;352:1744-6.
13. Ihle JN, Witthuhn BA, Quelle FW et al. Signaling through the hematopoietic cytokine receptors. Ann Rev Immunol 1995;13:369-98.
14. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29.
15. Parganas E, Wang D, Stravopodis D et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
16. Radosevic N, Winterstein D, Keller JR et al. JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor. Experimentel Hematology 2004;32:149-56.
17. Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med 1974;290:1382.
18. Correa PN, Eskinazi D, Axelrad AA. Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium. Blood 1994;83:99-112.
19. Dai CH, Krantz SB, Green WF et al. Polycythemia vera III: Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 1994;86:12-21.
20. Dai CH, Krantz SB, Dessypris EN et al. Polycythemia vera II: hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992;80:891-9.
21. Mirza AM, Correa PN, Axelrad AA. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor -1 receptor beta subunit in circulating mononuclear cells of patients with polycythemia vera. Blood 1995;86:877-82.
22. Moliterno AR, Hankins D, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-80.
23. Hayakawa F, Towatari M, Iida H et al. Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia. Br J Haematol 1998;101:521-8.
24. Xia Z, Baer MR, Block AW et al. Expression of signal transducers and activator of transcription proteins in acute myeloid leukaemia blasts. Cancer Res 1998;58:3173-80.
25. Gouilleaux-Gruart V, Gouilleaux F, Desaint C et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996;87:1692-7.
26. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-20.
27. Ilaria RL Jr., van Etten RA. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-10.
28. Komura E, Chagraoui H, Mansat de Mas V et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Ex Hematol 2003;31:622-30.
29. Roder S, Steimle C, Meinhardt G et al. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol 2001;29:694-702.
30. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999;98:295-303.
31. Shirogane T, Fukada T, Muller JM et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999;11:709-19.
32. Fukada T, Hibi M, Yamanaka Y et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 1996;5:449-60.
33. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-115.
34. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945.
35. Ugo V, Marzac C, Theyssandier I et al. Multiple signaling pathways are involved in erythropoietin -independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87.
36. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomi of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002;30:229-36.
37. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggest the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2002;102:3793-6.
38. Goerttler PS, Steimle C, Marz E et al. The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood 2005;106:2862-4.
39. Pahl HP. Molecular markers in myeloproliferative disorders: from classification to prognosis? Hematology 2003;8:199-209.
40. Samuelsson J, Hasselbalch H, Bruserud O et al. A phase II trial of pegylated interferon alpha-2b in polycythemia vera and essentieal thrombocythemia. Blood 2004;104:1518.